Business
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
PRINCETON, N.J., November 05, 2025--Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/83834edca6c3b1d9c72986cc4edc912f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X1smPrkKe6reYaRbQ_Afeg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/83834edca6c3b1d9c72986cc4edc912f","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/p2rKO.mpyXifTi.7VKJB5g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/83834edca6c3b1d9c72986cc4edc912f","width":1200,"height":165}},"lazy":false},{"type":"text","content":"PRINCETON, N.J., November 05, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has priced a public offering (the "Offering") of senior unsecured notes in a combined aggregate principal amount of €5 billion (collectively, the "Notes"). The Notes will be issued by Bristol Myers Squibb’s wholly-owned subsidiary, BMS Ireland Capital Funding Designated Activity Company, in five tranches: (i) €750,000,000 aggregate principal amount of 2.973% Notes due 2030, (ii) €1,150,000,000 aggregate principal amount of 3.363% Notes due 2033, (iii) €1,150,000,000 aggregate principal amount of 3.857% Notes due 2038, (iv) €750,000,000 aggregate principal amount of 4.289% Notes due 2045, and (v) €1,200,000,000 aggregate principal amount of 4.581% Notes due 2055. The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by Bristol-Myers Squibb Company. Bristol Myers Squibb expects that the closing of the Offering will occur on November 10, 2025, subject to the satisfaction of customary closing conditions.","length":1072,"tagName":"p"},{"type":"text","content":"On November 3, 2025, Bristol Myers Squibb commenced a tender offer (the "Tender Offer") to purchase, for cash, various series of its outstanding notes (the "Tender Offer Notes"). Bristol Myers Squibb intends to use the net proceeds of the Offering, together with approximately $3.0 billion of cash on hand, (i) to fund the Tender Offer and/or other repurchase, repayment or redemption of the notes subject to the Tender Offer, (ii) to pay fees and expenses in connection therew...